期刊文献+

Adjuvant and neoadjuvant treatment in pancreatic cancer 被引量:11

Adjuvant and neoadjuvant treatment in pancreatic cancer
下载PDF
导出
摘要 Pancreatic adenocarcinoma is one of the most aggressive human malignancies,ranking 4th among causes for cancer-related death in the Western world including the United States.Surgical resection offers the only chance of cure,but only 15 to 20 percent of cases are potentially resectable at presentation.Different studies demonstrate and confirm that advanced pancreatic cancer is among the most complex cancers to treat and that these tumors are relatively resistant to chemotherapy and radiotherapy.Currently there is no consensus around the world on what constitutes"standard"adjuvant therapy for pancreatic cancer.This controversy derives from several studies,each fraught with its own limitations.Standards of care also vary somewhat with regard to geography and economy,for instance chemo-radiotherapy followed by chemotherapy or vice versa is considered the optimal therapy in North America while chemotherapy alone is the current standard in Europe.Regardless of the efforts in adjuvant and neoadjuvant improved therapy,the major goal to combat pancreatic cancer is to find diagnostic markers,identifying the disease in a pre-metastatic stage and making a curative treatment accessible to more patients.In this review,authors examined the different therapy options for advanced pancreatic patients in recent years and the future directions in adjuvant and neoadjuvant treatments for these patients. Pancreatic adenocarcinoma is one of the most aggressive human malignancies,ranking 4th among causes for cancer-related death in the Western world including the United States.Surgical resection offers the only chance of cure,but only 15 to 20 percent of cases are potentially resectable at presentation.Different studies demonstrate and confirm that advanced pancreatic cancer is among the most complex cancers to treat and that these tumors are relatively resistant to chemotherapy and radiotherapy.Currently there is no consensus around the world on what constitutes"standard"adjuvant therapy for pancreatic cancer.This controversy derives from several studies,each fraught with its own limitations.Standards of care also vary somewhat with regard to geography and economy,for instance chemo-radiotherapy followed by chemotherapy or vice versa is considered the optimal therapy in North America while chemotherapy alone is the current standard in Europe.Regardless of the efforts in adjuvant and neoadjuvant improved therapy,the major goal to combat pancreatic cancer is to find diagnostic markers,identifying the disease in a pre-metastatic stage and making a curative treatment accessible to more patients.In this review,authors examined the different therapy options for advanced pancreatic patients in recent years and the future directions in adjuvant and neoadjuvant treatments for these patients.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第14期1565-1572,共8页 世界胃肠病学杂志(英文版)
基金 Supported by Instituto Salud CarlosⅢ
关键词 Pancreatic ductal adenocarcinoma ADJUVANT NEOADJUVANT Fluorouracil GEMCITABINE 辅助治疗 胰腺癌 恶性肿瘤 癌症治疗 手术切除 治疗方案 化疗 标准
  • 相关文献

参考文献80

  • 1Jemal A,Siegel R,Ward E,Hao Y,Xu J,Thun MJ.Cancer statistics,2009.CA Cancer J Clin2009;59:225-249.
  • 2Heinemann V,Boeck S,Hinke A,Labianca R,Louvet C.Meta-analysis of randomized trials:evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.BMC Cancer2008;8:82.
  • 3Sultana A,Tudur Smith C,Cunningham D,Starling N,Ne-optolemos JP,Ghaneh P.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer:re-sults of secondary end points analyses.Br J Cancer2008;99:6-13.
  • 4Stathis A,Moore MJ.Advanced pancreatic carcinoma:cur-rent treatment and future challenges.Nat Rev Clin Oncol2010;7:163-172.
  • 5Bilimoria KY,Bentrem DJ,Ko CY,Stewart AK,Winchester DP,Talamonti MS.National failure to operate on early stage pancreatic cancer.Ann Surg2007;246:173-180.
  • 6Shrikhande SV,Kleeff J,Reiser C,Weitz J,Hinz U,Esposito I,Schmidt J,Friess H,Büchler MW.Pancreatic resection for M1pancreatic ductal adenocarcinoma.Ann Surg Oncol2007;14:118-127.
  • 7Loos M,Kleeff J,Friess H,Büchler MW.Surgical treatment of pancreatic cancer.Ann N Y Acad Sci2008;1138:169-180.
  • 8Kalser MH,Ellenberg SS.Pancreatic cancer.Adjuvant com-bined radiation and chemotherapy following curative resec-tion.Arch Surg1985;120:899-903.
  • 9Neoptolemos JP,Dunn JA,Stocken DD,Almond J,Link K,Beger H,Bassi C,Falconi M,Pederzoli P,Dervenis C,Fernandez-Cruz L,Lacaine F,Pap A,Spooner D,Kerr DJ,Friess H,Büchler MW.Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:a randomised controlled trial.Lancet2001;358:1576-1585.
  • 10Neoptolemos JP,Stocken DD,Friess H,Bassi C,Dunn JA,Hickey H,Beger H,Fernandez-Cruz L,Dervenis C,Lacaine F,Falconi M,Pederzoli P,Pap A,Spooner D,Kerr DJ,Büchler MW.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.N Engl J Med2004;350:1200-1210.

同被引文献48

  • 1Olga P Zakharova,Grigory G Karmazanovsky,Viacheslav I Egorov.Pancreatic adenocarcinoma:Outstanding problems[J].World Journal of Gastrointestinal Surgery,2012,4(5):104-113. 被引量:5
  • 2Hui-Hua Cai,Yue-Ming Sun,Yi Miao,Wen-Tao Gao,Quan Peng,Jie Yao and Han-Lin Zhao Department of General Surgery,First Affiliated Hospital, Nanjing Medical University,Nanjing 210029,China,Department of General Surgery, Jiangsu Province Hospital of Traditional Chinese Medicine,Nanjing 210029, China.Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines[J].Hepatobiliary & Pancreatic Diseases International,2011,10(1):95-100. 被引量:4
  • 3Cheng-Yi Sun,Bai-Lin Wang,Chao-Quan Hu,Rui-Yun Peng,Ya-Bing Gao,Qing-Yang Gu,De-Wen Wang From the Department of Surgery, Guiyang Medical College, Guiyang 550004, China Beijing Institute of Radiation Medicine, Beijing 100850, China.Expression of the bcl-2 gene and its significance in human pancreatic carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2002,1(2):306-308. 被引量:4
  • 4Ioannis Koutsounas,Constantinos Giaginis,Efstratios Patsouris,Stamatios Theocharis.Current evidence for histone deacetylase inhibitors in pancreatic cancer[J].World Journal of Gastroenterology,2013,19(6):813-828. 被引量:9
  • 5Matthias Ocker.Deacetylase inhibitors-focus on non-histone targets and effects[J].World Journal of Biological Chemistry,2010,1(5):55-61. 被引量:11
  • 6PaolaGallinari,StefaniaDiMarco,PhillipJones,MichelePallaoro,ChristianSteinkühler.HDACs,histone deacetylation and gene transcription: from molecular biology to cancer therapeutics[J].Cell Research,2007,17(3):195-211. 被引量:36
  • 7Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.Cancer statistics, 2013[J]. CA: A Cancer Journal for Clinicians . 2013 (1)
  • 8Shin Hamada,Kennichi Satoh,Shin Miura,Morihisa Hirota,Atsushi Kanno,Atsushi Masamune,Kazuhiro Kikuta,Kiyoshi Kume,Jun Unno,Shinichi Egawa,Fuyuhiko Motoi,Michiaki Unno,Tooru Shimosegawa.miR‐197 induces epithelial–mesenchymal transition in pancreatic cancer cells by targeting p120 catenin[J]. J. Cell. Physiol. . 2013 (6)
  • 9Nagaraj Nagathihalli,Merchant,Jason Castellanos.Emerging targets in pancreatic cancer: epithelial–mesenchymal transition and cancer stem cells[J].OncoTargets and Therapy (default).2013(default)
  • 10Somnath Mukherjee,Christopher N Hurt,John Bridgewater,Stephen Falk,Sebastian Cummins,Harpreet Wasan,Tom Crosby,Catherine Jephcott,Rajarshi Roy,Ganesh Radhakrishna,Alec McDonald,Ruby Ray,George Joseph,John Staffurth,Ross A Abrams,Gareth Griffiths,Tim Maughan.Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J].Lancet Oncology.2013(4)

引证文献11

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部